152
Participants
Start Date
April 30, 2025
Primary Completion Date
September 30, 2028
Study Completion Date
January 31, 2032
Carboplatin
Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
Paclitaxel
Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
Cemiplimab
Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
Curative hypofractionated radiotherapy
Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
Cemiplimab (maintenance)
Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
Angers - Centre Paul Papin, Angers
Angers - CHU, Angers
Avignon - CH, Avignon
Boulogne - Ambroise Paré, Boulogne
Brest - CHU, Brest
Caen - CHU, Caen
Caen - CRLCC, Caen
Créteil - CHI, Créteil
Dijon - CRLCC, Dijon
Le Mans - CHG, Le Mans
Lille - CRLCC, Lille
Marseille - APHM, Marseille
Mulhouse - GHRMSA, Mulhouse
Paris - Bichat, Paris
Paris - Hôpital Cochin, Paris
Paris - Tenon, Paris
Bordeaux - CHU, Pessac
Lyon - HCL, Pierre-Bénite
Rennes - CHU, Rennes
Rouen - Centre Henri Becquerel, Rouen
Nantes - CRLCC, Saint-Herblain
Strasbourg - CRLCC, Strasbourg
Toulouse - CHU, Toulouse
Tours - CHU, Tours
Vandoeuvre-lès-Nancy - CRLCC, Vandœuvre-lès-Nancy
Metz - Hôpital Robert Schuman, Vantoux
Intergroupe Francophone de Cancerologie Thoracique
OTHER